You are here

  • Home
  • Archive
  • Volume 82, Issue 7
  • Response to: ‘Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial’’ by Zhao and Huang

Article metrics

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial’’ by Zhao and Huang
Free

 

Online download statistics by month:

Online download statistics by month: June 2021 to August 2024

AbstractFullPdf
Jun 202117217232
Jul 202138738570
Aug 202122422340
Sep 2021808016
Oct 2021989535
Nov 202111111130
Dec 202112912910
Jan 2022586227
Feb 202242417
Mar 202237363
Apr 202265649
May 2022656527
Jun 2022393810
Jul 202229299
Aug 202238379
Sep 2022393912
Oct 202227268
Nov 202242405
Dec 202225252
Jan 202341416
Feb 202334345
Mar 202332327
Apr 2023313112
May 202331319
Jun 202321921931
Jul 202310610532
Aug 2023596020
Sep 2023313419
Oct 2023353520
Nov 2023434224
Dec 2023444020
Jan 2024333127
Feb 2024302914
Mar 2024191959
Apr 2024302828
May 2024141424
Jun 2024141414
Jul 2024202015
Aug 202421229
Total25942578756